Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters

F. Sanfilippo, K. J. Kao, S. V. Pizzo, J. J. Collins

Research output: Contribution to journalArticle

Abstract

Hematologic and coagulation parameters of DBA/2J mice with Friend murine leukemia virus (F-MuLV) were compared to those of mice protected against development of virus-induced disease by passive administration of chimpanzee anti-F-MuLV antiserum (CaF-MuLV), as well as to those of uninfected serum-treated controls. At 2 weeks after F-MuLV inoculation, infected mice treated with normal chimpanzee serum (NCS) showed significant splenomegaly with a mild increase in peripheral white blood cells (leukocytosis) and a decrease in platelets (thrombocytopenia), but no difference was observed in prothrombin (PT) time or activated partial thromboplastin (APTT) time as compared to those of uninfected controls. Mice infected with F-MuLV but treated with CaF-MuLV had no splenomegaly or leukocytosis and demonstrated normal PT and APTT values, though moderate thrombocytopenia was evident. By 4 weeks after infection, mice treated with NCS showed marked splenomegaly and leukocytosis accompanied by moderate anemia, whereas mice that received CaF-MuLV had only a mild leukocytosis. Neither group showed a significant difference in platelet count, PT, or APTT values as compared to those of uninfected controls. F-MuLV-infected N:NIH(S) nude athymic mice given NCS showed significant mortality (70%) by 4 weeks after inoculation, with survivors having marked splenomegaly, mild leukocytosis, and thrombocytopenia but normal PT and APTT values. Virus-infected N:NIH(S) nude mice treated with CaF-MuLV had reduced mortality (20%), with survivors demonstrating mild splenomegaly and moderate thrombocytopenia but normal PT and APTT values. Moreover, no qualitative differences in platelet function, as measured by ADP stimulation, were seen in infected mice treated with NCS or CaF-MuLV or in uninfected controls. These data suggest that the intrinsic and extrinsic clotting systems in the mouse do not appear to be affected by F-MuLV-induced erythroleukemia and that the mild to moderate thrombocytopenia seen may not play a significant role in the pathobiology of this disease.

Original languageEnglish (US)
Pages (from-to)547-553
Number of pages7
JournalJournal of the National Cancer Institute
Volume64
Issue number3
StatePublished - 1980
Externally publishedYes

Fingerprint

Friend murine leukemia virus
Pan troglodytes
Immunotherapy
Leukemia
Splenomegaly
Leukocytosis
Thrombocytopenia
Serum
Thromboplastin
Immune Sera
Prothrombin
Nude Mice
Therapeutics
Survivors
Blood Platelets
Leukemia, Erythroblastic, Acute
Inbred DBA Mouse
Partial Thromboplastin Time
Mortality
Prothrombin Time

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters. / Sanfilippo, F.; Kao, K. J.; Pizzo, S. V.; Collins, J. J.

In: Journal of the National Cancer Institute, Vol. 64, No. 3, 1980, p. 547-553.

Research output: Contribution to journalArticle

@article{cd724c29e0d04f67b3985de6aedf0bc3,
title = "Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters",
abstract = "Hematologic and coagulation parameters of DBA/2J mice with Friend murine leukemia virus (F-MuLV) were compared to those of mice protected against development of virus-induced disease by passive administration of chimpanzee anti-F-MuLV antiserum (CaF-MuLV), as well as to those of uninfected serum-treated controls. At 2 weeks after F-MuLV inoculation, infected mice treated with normal chimpanzee serum (NCS) showed significant splenomegaly with a mild increase in peripheral white blood cells (leukocytosis) and a decrease in platelets (thrombocytopenia), but no difference was observed in prothrombin (PT) time or activated partial thromboplastin (APTT) time as compared to those of uninfected controls. Mice infected with F-MuLV but treated with CaF-MuLV had no splenomegaly or leukocytosis and demonstrated normal PT and APTT values, though moderate thrombocytopenia was evident. By 4 weeks after infection, mice treated with NCS showed marked splenomegaly and leukocytosis accompanied by moderate anemia, whereas mice that received CaF-MuLV had only a mild leukocytosis. Neither group showed a significant difference in platelet count, PT, or APTT values as compared to those of uninfected controls. F-MuLV-infected N:NIH(S) nude athymic mice given NCS showed significant mortality (70{\%}) by 4 weeks after inoculation, with survivors having marked splenomegaly, mild leukocytosis, and thrombocytopenia but normal PT and APTT values. Virus-infected N:NIH(S) nude mice treated with CaF-MuLV had reduced mortality (20{\%}), with survivors demonstrating mild splenomegaly and moderate thrombocytopenia but normal PT and APTT values. Moreover, no qualitative differences in platelet function, as measured by ADP stimulation, were seen in infected mice treated with NCS or CaF-MuLV or in uninfected controls. These data suggest that the intrinsic and extrinsic clotting systems in the mouse do not appear to be affected by F-MuLV-induced erythroleukemia and that the mild to moderate thrombocytopenia seen may not play a significant role in the pathobiology of this disease.",
author = "F. Sanfilippo and Kao, {K. J.} and Pizzo, {S. V.} and Collins, {J. J.}",
year = "1980",
language = "English (US)",
volume = "64",
pages = "547--553",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters

AU - Sanfilippo, F.

AU - Kao, K. J.

AU - Pizzo, S. V.

AU - Collins, J. J.

PY - 1980

Y1 - 1980

N2 - Hematologic and coagulation parameters of DBA/2J mice with Friend murine leukemia virus (F-MuLV) were compared to those of mice protected against development of virus-induced disease by passive administration of chimpanzee anti-F-MuLV antiserum (CaF-MuLV), as well as to those of uninfected serum-treated controls. At 2 weeks after F-MuLV inoculation, infected mice treated with normal chimpanzee serum (NCS) showed significant splenomegaly with a mild increase in peripheral white blood cells (leukocytosis) and a decrease in platelets (thrombocytopenia), but no difference was observed in prothrombin (PT) time or activated partial thromboplastin (APTT) time as compared to those of uninfected controls. Mice infected with F-MuLV but treated with CaF-MuLV had no splenomegaly or leukocytosis and demonstrated normal PT and APTT values, though moderate thrombocytopenia was evident. By 4 weeks after infection, mice treated with NCS showed marked splenomegaly and leukocytosis accompanied by moderate anemia, whereas mice that received CaF-MuLV had only a mild leukocytosis. Neither group showed a significant difference in platelet count, PT, or APTT values as compared to those of uninfected controls. F-MuLV-infected N:NIH(S) nude athymic mice given NCS showed significant mortality (70%) by 4 weeks after inoculation, with survivors having marked splenomegaly, mild leukocytosis, and thrombocytopenia but normal PT and APTT values. Virus-infected N:NIH(S) nude mice treated with CaF-MuLV had reduced mortality (20%), with survivors demonstrating mild splenomegaly and moderate thrombocytopenia but normal PT and APTT values. Moreover, no qualitative differences in platelet function, as measured by ADP stimulation, were seen in infected mice treated with NCS or CaF-MuLV or in uninfected controls. These data suggest that the intrinsic and extrinsic clotting systems in the mouse do not appear to be affected by F-MuLV-induced erythroleukemia and that the mild to moderate thrombocytopenia seen may not play a significant role in the pathobiology of this disease.

AB - Hematologic and coagulation parameters of DBA/2J mice with Friend murine leukemia virus (F-MuLV) were compared to those of mice protected against development of virus-induced disease by passive administration of chimpanzee anti-F-MuLV antiserum (CaF-MuLV), as well as to those of uninfected serum-treated controls. At 2 weeks after F-MuLV inoculation, infected mice treated with normal chimpanzee serum (NCS) showed significant splenomegaly with a mild increase in peripheral white blood cells (leukocytosis) and a decrease in platelets (thrombocytopenia), but no difference was observed in prothrombin (PT) time or activated partial thromboplastin (APTT) time as compared to those of uninfected controls. Mice infected with F-MuLV but treated with CaF-MuLV had no splenomegaly or leukocytosis and demonstrated normal PT and APTT values, though moderate thrombocytopenia was evident. By 4 weeks after infection, mice treated with NCS showed marked splenomegaly and leukocytosis accompanied by moderate anemia, whereas mice that received CaF-MuLV had only a mild leukocytosis. Neither group showed a significant difference in platelet count, PT, or APTT values as compared to those of uninfected controls. F-MuLV-infected N:NIH(S) nude athymic mice given NCS showed significant mortality (70%) by 4 weeks after inoculation, with survivors having marked splenomegaly, mild leukocytosis, and thrombocytopenia but normal PT and APTT values. Virus-infected N:NIH(S) nude mice treated with CaF-MuLV had reduced mortality (20%), with survivors demonstrating mild splenomegaly and moderate thrombocytopenia but normal PT and APTT values. Moreover, no qualitative differences in platelet function, as measured by ADP stimulation, were seen in infected mice treated with NCS or CaF-MuLV or in uninfected controls. These data suggest that the intrinsic and extrinsic clotting systems in the mouse do not appear to be affected by F-MuLV-induced erythroleukemia and that the mild to moderate thrombocytopenia seen may not play a significant role in the pathobiology of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0018865438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018865438&partnerID=8YFLogxK

M3 - Article

C2 - 6928240

AN - SCOPUS:0018865438

VL - 64

SP - 547

EP - 553

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -